• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Appl Thromb Hemost . Prognostic Value of Serum Salusin-α and Salusin-β in COVID-19 Patients

tetano

Editor, Senior Moderator
Clin Appl Thromb Hemost


. 2026 Jan-Dec:32:10760296261448753.
doi: 10.1177/10760296261448753. Epub 2026 May 8.
Prognostic Value of Serum Salusin-α and Salusin-β in COVID-19 Patients

Safiye Bilge Guclu Kayta[SUP] 1 [/SUP], Sevil Alkan Varoglu[SUP] 2 [/SUP], Havva Yasemin Cinpolat[SUP] 3 [/SUP], Taylan Onder[SUP] 1 [/SUP], Isil Deniz Aliravci[SUP] 2 [/SUP]


Affiliations
Free article Abstract

BackgroundVascular inflammation has an important role in the development and progression of coronavirus disease 2019 (COVID-19). Also, a high cytokine level predicts a poor prognosis for COVID-19. In this study, we aimed to investigate the effect of salusin-α and salusin-β peptides in determining the severity of the disease in the acute period of COVID-19.MethodThe investigation involved studying a group of 74 hospitalized individuals who had tested positive for SARS-CoV-2 through polymerase chain reaction (PCR) tests. The patients were divided into two groups: those who did not reach the primary endpoint and were discharged without complications and those who reached the primary endpoint (a composite of ICU admission and/or mortality). Salusin-α and salusin-β levels of serum samples taken at the time of application were statistically compared.OutcomeThere was no statistically significant difference in salusin-α levels between the groups (p=0.279). However, salusin-β levels were found to be significantly higher in patients who reached the primary endpoint compared to those who did not reach the primary endpoint and the healthy control group.ConclusionThe results of the analysis showed that a salusin-β level of 12.45 ng/mL predicts the risk of complications such as intensive care unit admission or mortality, with a sensitivity of 83.8% and a specificity of 40.5% for the estimation of the primary endpoint. The obtained data support our hypothesis, but observational studies with larger sample sizes are needed to evaluate salusins' determination of COVID-19 prognosis.

Keywords: COVID-19; biomarker; coronavirus; prognosis; salusin.

 
Back
Top